Form 4: MindMed's Chief Legal Officer, Mark Sullivan, Acquires 150,000 Restricted Stock Units
SEC Form 4 Filing
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., reports the acquisition of 150,000 restricted stock units (RSUs) on March 12, 2025.
Summary
- On March 12, 2025, Mark Sullivan, the Chief Legal Officer of Mind Medicine (MindMed) Inc., acquired 150,000 restricted stock units (RSUs).
- Each RSU represents a contingent right to receive one common share of MindMed.
- The RSUs vest in 16 equal quarterly installments starting on June 1, 2025, contingent upon Sullivan's continuous service to the company.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The grant of RSUs to a key executive is a common practice and suggests confidence in the company's future, but it's not a major event.
Positives
- The acquisition of RSUs by a key executive signals confidence in the company's future.
Future Outlook
The vesting schedule of the RSUs suggests a long-term commitment from the Chief Legal Officer to the company.
Industry Context
Grants of restricted stock units are a common form of executive compensation in the biotechnology and pharmaceutical industries, aligning executive interests with shareholder value.
Stakeholder Impact
- The RSU grant aligns the interests of the Chief Legal Officer with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date of transaction: Mark Sullivan acquired 150,000 RSUs. |
| 03/13/2025 | Date of signature for the Form 4 filing. |
| 06/01/2025 | First vesting date for the RSUs, with vesting occurring in 16 equal quarterly installments. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.